source
- Zealand Pharma shares tumble 12% after Boehringer obesity drug trial meets endpoints but disappoints analystsA phase 3 trial of Boehringer Ingelheim's dual‑agonist drug survodutide in people with obesity and type 2 diabetes was presented at the European Association for the Study of Diabetes meeting in Mil…
- United Therapeutics wins Delaware court case; BMS secures pediatric approval for CamzyosUnited Therapeutics secured a legal victory in a federal court in Delaware, with the judge ruling in the company's favor. The decision marks a notable win for the biotech firm, though the specific…